<DOC>
	<DOCNO>NCT01587508</DOCNO>
	<brief_summary>The purpose study ass efficacy end tolerability new drug contain combination meloxicam cyclobenzaprine ( 7,5/10mg ) component alone treatment acute lumbago .</brief_summary>
	<brief_title>Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago</brief_title>
	<detailed_description>To assess efficacy tolerability new drug contain combination meloxicam cyclobenzaprine treatment acute lumbago , compare component alone . Some eligibility criterion : Have normal X-ray lumbar spine age ; Have baseline score VAS high equal 40 mm</detailed_description>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>Sign , initial date Informed Consent Form ( ICF ) ; Be 18 75 year old ; Have acute lumbago onset less 72 hour ; Have normal Xray ; Have baseline score VAS high equal 40 mm ; Use triptans ; Use monoamine oxidase inhibitor ; Use NSAIDs within last week ; Previous use narcotic ; Have rheumatologic disease ; Conditions chronic pain ; Have significant chronic comorbidity ; Previous history gastrointestinal bleed ulcer ; History allergy component study medication ; Recent history myocardial infarction , cardiac arrhythmia , cardiac conduction block change , congestive heart failure ; Female patient pregnant breastfeed wish become pregnant deny use safe contraceptive method study enrol study ; Have participate another clinical trial within last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>